Original articles

2017

Forner K., Holm R., Morakul B., Junyaprasert V., Ackermann M., Mazur J., Langguth P. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. Eur. J. Pharm. Sci. (2017) 101: 211-219

Forner K., Hidalgo I., Lin J., Ackermann M., Langguth P. Dissolution/permeation: The importance of the experimental setup for the prediction of formulation effects on fenofibrate in vivo performance. Die Pharmazie (2017) 72, doi 10.1691/ph.2017.7066

Ziller A, Nogueira SS, Huehn E, Funari SS, Brezesinski G, Hartmann H, Sahin U, Haas H, Langguth P. Incorporation of mRNA in lamellar lipid matrices for parenteral administration. Mol Pharm (2017) doi 10.1021/acs.molpharmaceut.7b01022

Zaheer K, Langguth P. Formulation strategy towards minimizing viscosity mediated negative food effect on disintegration and dissolution of immediate release tablets. Drug Dev Ind Pharm. (2017) doi 10.1080/03639045.2017.1397685

Hofsäss MA, Souza J, Silva-Barcellos NM, Bellavinha KR, Abrahamsson B, Cristofoletti R, Groot DW, Parr A, Langguth P, Polli JE, Shah VP, Tajiri T, Mehta MU, Dressman JB. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid. J Pharm Sci. (2017) 106(12):3421-3430. doi 10.1016/j.xphs.2017.08.007

Radu IC, Hudita A, Zaharia C, Stanescu PO, Vasile E, Iovu H, Stan M, Ginghina O, Galateanu B, Costache M, Langguth P, Tsatsakis A, Velonia K, Negrei C. Poly(HydroxyButyrate-co-HydroxyValerate) (PHBHV) Nanocarriers for Silymarin Release as Adjuvant Therapy in Colo-rectal Cancer. Front Pharmacol. (2017) doi: 10.3389/fphar.2017.00508

Dahlgren D, Roos C, Lundqvist A, Tannergren C, Langguth P, Sjöblom M, Sjögren E, Lennernäs H. Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker (51)Cr-EDTA. Mol Pharm. (2017) 14(12):4243-4251. doi:10.1021/acs.molpharmaceut.7b00353

Rausch J, Lopez PA, Bialojan A, Denny M, Langguth P, Probst HC, Schild H, Radsak MP. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization. J Dermatol Sci. (2017) 87(3):300-306. doi: 10.1016/j.jdermsci.2017.06.013

Lopez PA, Denny M, Hartmann AK, Alflen A, Probst HC, von Stebut E, Tenzer S, Schild H, Stassen M, Langguth P, Radsak MP. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. J Dermatol Sci. (2017) 87(3):252-259. doi:10.1016/j.jdermsci.2017.06.012

Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. (2017) 12:1565-1577. doi: 10.2147/COPD.S115886

Thambavita D, Galappatthy P, Mannapperuma U, Jayakody L, Cristofoletti R, Abrahamsson B, Groot DW, Langguth P, Mehta M, Parr A, Polli JE, Shah VP, Dressman. J. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. J Pharm Sci. (2017) 106(10):2930-2945. doi:10.1016/j.xphs.2017.04.068

Verbeeck RK, Kanfer I, Löbenberg R, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Polli JE, Parr A, Shah VP, Mehta M, Dressman JB. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. J Pharm Sci. (2017) 106(8):1933-1943. doi: 10.1016/j.xphs.2017.04.019

Azran C, Langguth P, Dahan A. Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass. Surg Obes Relat Dis. (2017) 13(7):1245-1247.doi: 10.1016/j.soard.2017.03.003

Burak C, Wolffram S, Zur B, Langguth P, Fimmers R, Alteheld B, Stehle P, Egert S. Effects of the flavonol quercetin and α-linolenic acid on n-3 PUFA status in metabolically healthy men and women: a randomised, double-blinded, placebo-controlled, crossover trial. Br J Nutr. (2017) 117(5):698-711. doi: 10.1017/S0007114517000241

Nguyen MA, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J, Crison J, Holm R, Li R, Mannaert E, McAllister M, Mueller-Zsigmondy M, Muenster U, Ojala K, Page S, Parr A, Rossenu S, Timmins P, Van Peer A, Vermeulen A, Langguth P. A survey on IVIVC/IVIVR development in the pharmaceutical industry – Past experience and current perspectives. Eur J Pharm Sci. (2017) 102:1-13. doi:10.1016/j.ejps.2017.02.029

Al-Gousous J, Tsume Y, Fu M, Salem II, Langguth P. Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems. Mol Pharm. (2017) 14(12):4209-4219. doi: 10.1021/acs.molpharmaceut.6b00877

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. Eur J Pharm Sci. (2017) 96:610-625. doi: 10.1016/j.ejps.2016.10.036

Forner K, Roos C, Dahlgren D, Kesisoglou F, Konerding MA, Mazur J, Lennernäs H, Langguth P. Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Dev Ind Pharm. (2017) 43(2):338-346. doi:10.1080/03639045.2016.1251449

2016

K. Spicher, S. Brendler-Schwaab, C. Schlösser, M. Catarinolo, S. Fütterer, P. Langguth, H. Enzmann (2015): Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Reg. Toxicol. And Pharmacol. 73: 65-72

M. Knopp, P. Langguth et al. (2016): Influence of copolymer composition on in vitro and in vivo performance of celecoxib-PVP/VA amorphous solid dispersions. AAPS Journal in press

M. M. Knopp, J.H. Nguyen, C. Becker, N.M. Francke, E.B. Jørgensen, P. Holm, R. Holm, H. Mu, T. Rades, P. Langguth (2016): Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions. Eur. J. Pharm. Biopharm. In press

V. Brüll, C. Burak, B. Stoffel-Wagner, S. Wolffram, G. Nickenig, C. Müller, P. Langguth, B. Alteheld, R. Fimmers, P. Stehle, S. Egert (2016): Acute intake of quercetin from onion skin extract does not influence postprandial blood pressure and endothelial function in overweight-to-obese adults with hypertension: a randomized, double-blind, placebo-controlled, crossover trial. Eur. J. Nutr. DOI 10.1007/s00394-016-1185-1

S. Kindgen, R. Rach, T. Nawroth, B. Abrahamsson, P. Langguth (2016): A Novel Disintegration Tester for Solid Dosage Forms Enabling Adjustable Hydrodynamics. J. Pharm. Sci. (2016) 105(8) 2402-2409

V. Brüll, C. Burak, B. Stoffel-Wagner, S. Wolffram, G. Nickenig, C. Müller, P. Langguth, B. Alteheld, R. Fimmers, P. Stehle, S. Egert (2016): No effects of quercetin from onion skin extract on serum leptin and adiponectin concentrations in overweight-to-obese patients with (pre)hypertension: a randomized double-blinded placebo-controlled crossover trial. Eur. J. Nutr. DOI 10.1007/s00394-016-1267-0

Darwich AS, Margolskee A, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B. IMI -Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. Eur J Pharm Sci. (2016) 96: 626-642

Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine (2016) 20:2723-2734

Waisman A, Hövelmeyer N, Diefenbach A, Schuppan D, Reddehase MJ, Kleinert H, Kaina B, Grabbe S, Galle PR, Theobald M, Zipp F, Sahin U, Türeci Ö, Kreiter S, Langguth P, Decker H, van Zandbergen G, Schild H. Past, present and future of immunology in Mainz. Cell Immunol. (2016) 308:1-6

Forner K, Roos C, Dahlgren D, Kesisoglou F, Konerding MA, Mazur J, Lennernäs H, Langguth P. Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Dev Ind Pharm. (2016) 6:1-9

Margolskee A, Darwich AS, Pepin X, Aarons L, Galetin A, Rostami-Hodjegan A, Carlert S, Hammarberg M, Hilgendorf C, Johansson P, Karlsson E, Murphy D, Tannergren C, Thörn H, Yasin M, Mazuir F, Nicolas O, Ramusovic S, Xu C, Pathak SM, Korjamo T, Laru J, Malkki J, Pappinen S, Tuunainen J, Dressman J, Hansmann S, Kostewicz E, He H, Heimbach T, Wu F, Hoft C, Laplanche L, Pang Y, Bolger MB, Huehn E, Lukacova V, Mullin JM, Szeto KX, Costales C, Lin J, McAllister M, Modi S, Rotter C, Varma M, Wong M, Mitra A, Bevernage J, Biewenga J, Van Peer A, Lloyd R, Shardlow C, Langguth P, Mishenzon I, Nguyen MA, Brown J, Lennernäs H, Abrahamsson B. IMI - Oral Biopharmaceutics Tools project - Evaluation of Bottom-up PBPK Prediction Success Part 2: An Introduction to the Simulation Exercise and Overview of Results. Eur J Pharm Sci. (2016) 96: 610-625

Al-Gousous J, Amidon GL, Langguth P. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms. Mol Pharm. (2016) 13(6):1927-36

Azran C, Wolk O, Zur M, Fine-Shamir N, Shaked G, Czeiger D, Sebbag G, Kister O, Langguth P, Dahan A. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev. (2016) 17:11, 1050-1066.

Gogoll K, Stein P, Lee KD, Arnold P, Peters T, Schild H, Radsak M, Langguth P. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization. Cell Immunol. (2016) 308:35-43.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. (2016) 16;534(7607):396-401.

Knopp MM, Chourak N, Khan F, Wendelboe J, Langguth P, Rades T, Holm R. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions. Eur J Pharm Biopharm. (2016) 105:106-14.

Knopp MM, Gannon N, Porsch I, Rask MB, Olesen NE, Langguth P, Holm R, Rades T. A Promising New Method to Estimate Drug-Polymer Solubility at Room Temperature. J Pharm Sci. (2016) 105(9):2621-4.

Al-Gousous J, Langguth P. Effect of Calcium Ions on the Disintegration of Enteric-Coated Solid Dosage Forms. J Pharm Sci. (2016) 105(2):509-11.

J. Al-Gousous, P. Langguth (2016) Empfehlungen zur Wirkstofffreisetzung. Kommentar zur PhEur 8.0, Wissenschaftliche Verlagsgesellschaft Stuttgart

A. Wiedemann, R. Kirschner-Hermanns, C. von Ostau, S. Alloussi, T. Bschleipfer, P. Langguth, I. Füsgen, A. Schroeder (2016) Überaktive Blase: Wissenswertes zu Anamnese, diagnostik und Therapie in der Praxis. Deutscher Ärzteverlag, Heft 2, 2. Jahrgang, 5/2016

C. Azran, O. Wolk, M. Zur, N. Fine-Shamir, G. Shaked, D. Czeiger, G. Sebbag, O. Kister, P. Langguth, A. Dahan (2016) Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obesity reviews doi 10.1111/obr.12434

Rodrigo Cristofoletti, Vinod P. Shah, Peter Langguth, James E. Polli, Mehul Mehta, Bertil Abrahamsson, Jennifer B. Dressman, and Pablo Quiroga (2015) Meeting Report: International Workshop on Implementation of Biowaivers Based on the Biopharmaceutics Classification System (BCS). Dissolution Technologies May (2015) dx.doi.org/10.14227/DT220215P77

Goodarzi N, Barazesh Morgani A, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Mehta MU, Polli JE, Shah VP, Dressman JB. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. J Pharm Sci. (2016) 105(4):1362-9.

2015

J. Al Gousous, M. Penning, P. Langguth (2015): Molecular insights into shellac film coats from different aqueous shellac salt solutions and effect on disintegration of enteric-coated soft gelatin capsules. Int. J. Pharm. 484(1-2): 283-291

M. Kubbinga, M.A. Nguyen, P. Staubach, S. Teerenstra, P. Langguth (2015): The Influence of chitosan on the oral bioavailability of acyclovir - A comparative bioavailability study in humans. Pharm. Res. DOI:10.1007/s11095-014-1613-y

J. Al-Gousous and P. Langguth (2015): European versus United States Pharmacopoeia-specified disintegration testing for enteric-coated soft gelatin capsules. Dissolution Technologies 22(3)

M. Knopp, N.E. Olesen, P. Holm, K. Loebmann, R. Holm, P. Langguth, T. Rades (2015): Evaluation of drug-polymer solubility curves through formal statistical analysis. Comparison of preparation techniques. J. Pharm. Sci. 104(1) 44-51

T. Peters, C. Grunewald, M. Blaikner, M. Ziegner, C. Schütz, D. Iffland, G. Hampel, T. Nawroth, P. Langguth (2015): Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy. Radiat. Oncol. 10(1):52 doi: 10.1186/s13014-015-0342-7

P. Khoshakhlagh, R. Johnson, P. Langguth, T. Nawroth, L. Schmueser, N. Hellmann, H. Decker, N.K. Szekely (2015): Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development. J Pharm Sci. 2015 May 11. doi: 10.1002/jps.24470

V. Brüll, C. Burak, B. Stoffel-Wagner, S. Wolffram, G. Nickenig, C. Müller, P. Langguth, B. Alteheld, S. Naaf, B.F.Zimmermann, P. Stehle, S. Egert (2015): Effects of a quercetin-rich onion skin extract on 24h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomized double-blinded placebo-controlled crossover trial. Br. J. Nutr. 114(8): 1263-77. Doi: 10.1017/S0007114515002950.

S. Kindgen, H. Wachtel, B. Abrahamsson, P. Langguth (2015): Computational Fluid dynamics simulation of hydrodynamics and stresses in the PhEur/USP disintegration tester under fed and fasted fluid characteristics. J Pharm Sci. 2015 May 27. doi:10.1002/jps.24511

K. Spicher, S. Brendler-Schwaab, C. Schlösser, M. Catarinolo, S. Fütterer, P. Langguth, H. Enzmann (2015): Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Reg. Toxicol and Pharmacol. 73: 65-72

M.A. Nguyen, P. Staubach, S. Wolffram, P. Langguth (2015): The influence of single-dose and short-term-administration of quercetin on the pharmacokinetics of midazolam in humans. J. Pharm. Sci. doi: 10.1002/jps.24500

M.M. Knopp, N.E. Olesen, P. Holm, P. Langguth, R. Holm, T. Rades (2015): Influence of polymer molecular weight on drug-polymer solubility: A comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer. J. Pharm. Sci. doi: 10.1002/jps.24410

T. Schmitz, N. Bassler, M. Blaickner, M. Ziegner, M.C. Hsiao, Y.H. Liu, H. Koivunoro, I. Auterinen, T. Serén, P. Kotiluoto, H. Palmans, P. Sharpe, P. Langguth, G. Hampel (2015): The alanine detector in BNCT dosimetry: dose response in thermal and epithermal neutron fields. Med Phys. 42(1):400-11

M.A. Nguyen, P. Staubach, I. Tamai, P. Langguth (2015): High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans. Eur. J. Pharm. Sci. 68: 36-42

M. Penning, P. Langguth (2015) Schellack. Kommentar zur PhEur 8.0, Wissenschaftliche Verlagsgesellschaft Stuttgart

M.D. Donovan, J.E. Polli, P. Langguth, I. Tamai, B. Vig, L.X. Yu (2015) Gordon L. Amidon: Very sustained drug absorption. J. Pharm. Sci. Doi: 10.1012/jps.24523

M. Petrusevska, S. Berglez, I. Krisch, I. Legen, K. Megusar, L. Peternel, B. Abrahamsson, R. Cristofoletti, D.W. Groot, S. Kopp, P. Langguth, M. Mehta, J.E. Polli, V.P. Shah, J. Dressman (2015) Biowaiver monographs for immediate release solid oral dosage forms: Levetiracetam. J. Pharm. Sci. Doi: 10.1002/jps.24350

Kindgen S, Wachtel H, Abrahamsson B, Langguth P. (2015): Computational Fluid Dynamics Simulation of Hydrodynamics and Stresses in the PhEur/USP Disintegration Tester Under Fed and Fasted Fluid Characteristics. J Pharm Sci

M. A. Nguyen, P. Staubach, S. Wolffram, P. Langguth (2015). The influence of single-dose and short-term administration of quercetin on the pharmacokinetics of midazolam in humans. J Pharm Sci. published online May 18th 2015.

M. Kubbinga, M. A. Nguyen, P. Staubach, S. Tereenstra, P. Langguth (2015). The influence of chitosan on the oral bioavailability of acyclovir – a comparative bioavailability study. Pharm Res. 32: 2241-2249.

2014

M. A. Nguyen, P. Staubach, I. Tamai, P. Langguth (2014). High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans. Eur J Pharm Sci. 68: 36-42.

A. Radwan, M. Wagner, G.L. Amidon, P. Langguth (2014): Bio-predictive tablet disintegration: Effect of water diffusivity, fluid flow, food composition and test conditions. Eur. J. Pharm. Sci. 57: 273-279

R. Johnson, T. Nawroth, P. Khoshakhlagh, P. Langguth, L. Schmueser, N. Hellmann, H. Decker, N.K. Szekely (2014): Amphotericin B microparticles “AmbiShell” from phospholipid and gelatin: Development and inverstigatioin by combined DLS and SANS resolves the core-shell structure. Eur. J. Lipid Sci Technol. 116: 1167-1173

P. Khoshakhlagh, R. Johnson, T. Nawroth, P. Langguth, L. Schmueser, N. Hellmann, H. Decker, N.K. Szekely (2014): Nanoparticle structure development in the gastro-intestinal model fluid FaSSIFmod6.5 from several phospholipids at various water content relevant for oral drug absorption. Eur. J. Lipid Sci. Technol. 116: 1155-1166

H. Lennernäs, L. Aarons, P. Augustijns, S. Beato, M. Bolger, K. Box, M. Brewster, J. Butler, J. Dressman, R. Holm, J. Frank, R. Kendall, P. Langguth, J. Sydor, A. Lindahl, M. McAllister, U. Muenster, A. Müllertz, K. Ojala, X. Pepin, C. Reppas, A. Rostami-Hodjegan, M. Verwei, W. Weitschies, C. Wilson, C. Karlsson, B. Abrahamsson. (2014): Oral biopharmaceutics tools - Time for a new initiative - An introduction to the IMI project OrBiTo. Eur J Pharm Sci. 57: 292-299.

Sediq A, Kubbinga M, Langguth P, Dressman J. (2014): The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs. J Pharm Sci. 103: 65-70

M.A. Nguyen, P. Staubach, S. Wolffram, P. Langguth (2014): Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci. 2014 61: 54-60

Y. Tsume, D.M. Mudie, P. Langguth, G.E. Amidon, G.L. Amidon (2014): The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 57: 152-163

E. Sjögren, B. Abrahamsson, P. Augustijns, D. Becker, M.B. Bolger, M. Brewster, J. Brouwers, T. Flanagan, M. Harwood, C. Heinen, R. Holm, H.P. Juretschke, M. Kubbinga, A. Lindahl, V. Lukacova, U. Münster, S. Neuhoff, M.A. Nguyen, A.v. Peer, C. Reppas, A.R. Hodjegan, C. Tannergren, W. Weitschies, C. Wilson, P. Zane, H. Lennernäs, P. Langguth (2014): In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 57: 99-151

M. Kubbinga, L. Moghani, P. Langguth (2014): Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: Lactose in solid oral dosage forms. Eur J Pharm Sci. 61: 27-31

S. Cvijić, J. Parojčić, P. Langguth P. (2014): Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification. Eur J Pharm Sci. 61: 40-53

H. Lennernäs, P. Langguth, S. Yamashita, D.J.A. Crommelin (2014): Theme issue 5th World Conference on Drug Absorption, Transport and Delivery. Eur. J. Pharm. Sci. 61: 1

S. Cvijić, Langguth P. (2014): Improvement of trospium-specific absorption models for fasted and fed states in humans. Biopharm. Drug Dispos. doi: 10.1002/bdd.1911

Morakul B., Suksiriworapong J., Chomnawang M.T., Langguth P., Junyaprasert V.B. (2014): Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. Eur. J. Pharm. Biopharm. Sep 5. pii: S0939-6411(14)00268-9. doi: 10.1016/j.ejpb.2014.08.013

J. Al-Gousous and P. Langguth (2014): Oral dosage form disintegration – the forgotten test. J. Pharm. Sci. in press

2013

C. Heinen, S. Reuss, S. Saaler-Reinhardt, P. Langguth (2013): Mechanistic basis for unexpected bioavailability enhancement of polyelectrolyte complexes incorporating BCS class III drugs and carrageenans. Eur. J. Pharm. Biopharm. 85: 26-33

C. Heinen, S. Reuss, G.L. Amidon, P. Langguth (2013):

Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride. Mol. Pharm. 10: 3989-3996

A. Radwan, S. Ebert, A. Amar, K. Münnemann, M. Wagner, G.L. Amidon, P. Langguth (2013):

Mechanistic understanding of food effects: Water diffusivity in GI is an important parameter for prediction of disintegration of solid oral dosage forms. Mol. Pharm. 10: 2283-2290S. Fütterer, I. Andrusenko, W. Hofmeister, P. Langguth (2013): Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anemia by Electron Diffraction (ED) and X-Ray Powder Diffraction (XRPD). J. Pharmaceut. Biomed. Anal. 86: 151-160

2012

S. Wein, R. Cermak, S. Wolffram, P. Langguth (2012):
Chronic querceting feeding decreases plasma concentrations of salicylamide phase II metabolites in pigs following oral administration. Xenobiotica 42: 477-482

T. Schmitz, M. Blaickner, M. Ziegner, N. Bassler, C. Grunewald, J. Kratz, C. Schütz, P. Langguth, P. Sharpe, H. Palmans, M.H. Holzscheiter, G. Otto, G. Hampel (2011):
Dose determination using alanine detectors in a mixed neutron and gamma field for boron neutron capture therapy of liver malignancies. Act. Oncol. 50: 17-22

A. Hartung, E. Johansson, H. Valthorsson, M. Knöll, P. Langguth (2012): “Design space” determination of a paracetamol fluid bed granulation using design of experiments. Pharm. Ind. 74: 644-650

A. Hartung, M. Knöll, U. Schmidt, P. Langguth (2012): Relevance of air-to-liquid mass ratio effect on final granule properties of an enalapril formulation. Drug Dev. Ind. Pharm. 38: 12-18

L. Mühlfeld, P. Langguth, H. Häusler, H.J. Hagels (2012): Influences of heat seal lacquer thickness on the quality of blister packages. Eur. J. Pharm. Sci. 45: 150-157

S. Egert, S. Wolffram, E.M. Hubbermann, K. Schwarz, P. Langguth, G. Rimbach, M.J. Müller (2012): Enriched cereal bars are more effective at increasing plasma quercetin compared with quercetin from powder filled hard capsules. Br. J. Nutr. 107: 539-546

K. Buch, T. Peters, T. Nawroth, M. Sänger, H. Schmidberger, P. Langguth (2012): Determination of cell survival after irradiation via clonogenic assay versus MTT assay – a comparative study. Radiation Oncology, 7: 1

L. Mühlfeld, P. Langguth, H. Häusler, H. Hagels (2012): Influence of blister package design on usability among older adults. Int. J. Clin. Pharm. 34: 553-560

M.R. Jahn, T. Nawroth, S. Fütterer, U. Wolfrum, U. Kolb, P. Langguth (2012): Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells. Mol. Pharm. 9: 1628-1637

K. Gogoll, P. Stein, H. Wei, H. Schild, M. Radsak, P. Langguth (2012): Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects. Biopharm. Drug Dispos. 33: 218-228

Y. Tsume, P. Langguth, A. Garcia-Arieta, G.L. Amidon (2012):
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm. Drug Dispos. 33: 366-377

A. Radwan, G.L. Amidon, P. Langguth (2012):
Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity. Biopharm. Drug Dispos. 33: 403-416

J. Gajendran, J. Krämer, P. Langguth (2012):
In vivo predictive release methods for medicated chewing gums. Biopharm. Drug Dispos. 33: 417-424

P. Langguth and P. Marroum (2012):
Relationships between in vitro drug dissolution and in vivo response. Biopharm. Drug Dispos. 33: 347-348

M. Kubbinga, P. Langguth, D. Barends (2012):
Risk analysis in bioequivalence and biowaiver decisions. Biopharm. Drug Dispos. 33: 254-261

2011

P. Stein, G. Rechtsteiner, T. Warger, T. Bopp, H.-C. Probst, M. Strassen, P. Langguth, H. Schild, M.P. Radsak (2011):UV exposure boosts transcutaneous immunization and improves tumor immunity: Cytotoxic T cell priming via the skin. J. Invest. Dermatol. 131(1): 211-219

A. Hartung, M. Knöll, U. Schmidt, P. Langguth (2011): Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an enalapril formulation. Drug Development Industrial Pharmacy 37: 274-280

B. Obermeier, P. Langguth, H. Frey (2011): Partially quarternized amino functional poly(methacrylate) terpolymers: Versatile drug permeability modifiers. Biomacromolecules 12: 425-431

P. Buch, P. Holm, J. Qvist Thomassen, D. Scherer, M. Kataoka, S. Yamashita, P. Langguth (2011): IVIVC in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution/permeation methods. Die Pharmazie 66: 11-16

M.R. Jahn, H.B. Andreasen, S. Fütterer, T. Nawroth, V. Schünemann, U. Kolb, W. Hofmeister, M. Munoz, K. Bock, M. Meldal, P. Langguth (2011):
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78: 480-491

C. Meyer, P. Buch, P. Langguth (2011):
Improvement of the wettability and dissolution of fenofibrate compacts by plasma treatment. Int. J. Pharmaceutics 416: 49-54

P. Stein, M. Weber, S.. Prüfer, B.. Schmid, E. Schmitt, H.C. Probst, A. Waisman, Langguth P., Schild HJ, Radsak M.P. (2011): Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization. PLoS One 1: e27911

M.R. Jahn, I. Shukoor, W. Tremel, U. Wolfrum, U. Kolb, T. Nawroth, P. Langguth (2011):
Hemin coupled iron(III)-hydroxide nanoparticles show increased uptake in Caco-2 cells.
J. Pharm. Pharmacol. 63: 1522-1530

T. Nawroth, P. Buch, K. Buch, P. Langguth, R. Schweins (2011):
Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIFmod estimated by combined time-resolved neutron and dynamic light scattering. Molecular Pharmaceutics 8: 2162-2172

2010

C. Weiler, M. Egen, M. Trunk, P. Langguth (2010):
Force control and powder dispersibility of spray dried particles for inhalation. J. Pharm. Sci. 99: 303-316

C. Weiler, M. Wolkenhauer, M. Trunk, P. Langguth (2010):New model describing the total dispersion of dry powder agglomerates. Powder Technology 203: 248-253

Yoshiyuki Shirasaka, Erika Kuraoka, Hildegard Spahn-Langguth, Takeo Nakanishi, Peter Langguth, and Ikumi Tamai (2010):
Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther. 332: 181-189

P. Buch, P. Holm, J. Q. Thomassen, D. Scherer, R. Branscheid, U. Kolb, P. Langguth (2010):
IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J. Pharm. Sci. 99: 4427-4436

A.M. Hofmann, F. Wurm, E. Hühn, T. Nawroth, P. Langguth, H. Frey (2010):
Hyperbranched polyglycerol-based lipids via oxyanionic polymerization: Towards a novel type of stealth liposomes? Biomacromolecules 11: 568-574

E. Hühn, H-G. Buchholz, G. Shazly, S. Maus, O. Thews, N. Bausbacher, F. Rösch, M. Schreckenberger, P. Langguth (2010):
Predicting the In Vivo Release From a Liposomal Formulation by IVIVC and Non-Invasive Positron Emission Tomography Imaging. Eur. J. Pharm. Sci. 41: 71-77

Y. Li, Y. Shirasaka, P. Langguth, I. Tamai (2010):
Quantitation of talinolol in rat plasma by LC-MS-MS. J. Chromatogr. Sci. 48: 367-370

L. Mühlfeld, P. Langguth, H. Häusler, H. Hagels (2010):
Comparison of quantitative analysis techniques fort he determination of heat seal laquer layers on aluminium blister foils. Eur. J. Pharm. Sci. 41: 700-706

2009

K. Buch, M. Penning, E. Wächtersbach, M. Maskos, P. Langguth (2009):
Investigation of various shellac grades: Additional analysis for identity. Drug Development Industrial Pharmacy 35: 694-703

I. Kovacevic, J. Parojcic, I. Homsek, M. Tubic-Grozdanis, P. Langguth (2009):
Justification of biowaiver for carbamazepine – a low soluble high permeable compound – in solid dosage forms based on IVIVC and gastrointestinal simulation. Molecular Pharmaceutics 6: 40 – 47

D. Barends, C. Crevoisier, J. Dressman, T. Faust, A. Stodik, M. Zimmer, P. Langguth (2009):
Evaluation of Bioequivalence of drug products. Pharm. Ind. 71: 258-263

I. Kovacevic, J. Parojcic, M. Tubic-Grozdanis, P. Langguth (2009):
An investigation into the importance of “very rapid dissolution” criteria for drug bioequivalence demonstration using Gastrointestinal Simulation Technology. AAPS Journal 11: 381-384

C. Weiler, M. Egen, M. Trunk, P. Langguth (2009):
Force control and powder dispersibility of spray dried particles for inhalation. J. Pharm. Sci. PMID 19533606

R. Cermak, S. Wein, S. Wolffram, P. Langguth (2009):
Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur. J. Pharm. Sci. in press

2008

S. Roth, P. Langguth, K. Spicher, H. Enzmann (2008):
Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells. Translational Research 151 (1): 36-44.

F.E. Alemdaroglu, N.C. Alemdaroglu, P. Langguth, A. Herrmann (2008):
Cellular uptake of DNA block copolymer micelles with different shapes. Macromolecular Rapid Communications, 29: 326-329.

N. Glube, P. Langguth (2008):
Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3. Nephron Physiol. 108: 18-28.

M. Tubic-Grozdanis, J.M. Hilfinger, G.L. Amidon, J. Seung Kim, P. Kijek, P. Staubach, P. Langguth (2008):
Pharmacokinetics of the CYP3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 25: 1591-1600.

S. Grube, U. Wolfrum, P. Langguth (2008):
Characterization of the epithelial permeation enhancing effect of basic butylated methacrylate copolymer – in vitro studies. Biomacromolecules 9: 1398-1405

F.E. Alemdaroglu, N.C. Alemdaroglu, P. Langguth, A. Herrmann (2008):
DNA Block Copolymer Micelles - A combinatorial tool for cancer nanotechnology. Adv. Mat. 20: 899-902.

N.C. Alemdaroglu, U. Dietz, S. Wolffram, H. Spahn-Langguth, P. Langguth (2008):
Influence of green and black tea on folic acid phrmacokinetics in healthy volnteers: potential risk of diminished folic acid bioavilaility. Biopharm. Drug Dispos. 29: 335-348.

M. Tubic-Grozdanis, M. Bolger, P. Langguth (2008):
Application of gastrointestinal simulation for BCS classification. AAPS Journal 10: 213-226

G. Shazly, P. Langguth (2008):
Comparison between dialysis and dispersion methods for in vitro release determination of drugs from multilamellar liposomes. Dissolution Technologies 15: 7-10

M.I. Shukoor, F. Natalio, N. Glube, M. Nawaz Thair, H.A. Therese, V. Ksenofontov, P. Theato, P. Langguth, J.-P. Boissel, H.C. Schröder, W.E.G. Müller, W. Tremel (2008):
dsRNA Functionalized multifunctional g-Fe2O3 nanocrystals: a tool for targeting cell surface receptors. Angewandte Chemie Int. Ed. 47: 4748-4752.

M. Ofer, P. Langguth, K. Hennes, H. Spahn-Langguth (2008):
Transgenic ovarian carcinoma cells: Characterization of an experimental model to define P-glycoprotein-related transport. Methods and Findings, in revision.

M. Ofer, P. Langguth, S. Wolffram, H. Spahn-Langguth (2008):
Flavonoids' concentration dependent inhibiting effects also include cellular uptake: Studies based on parental vs. MDR1-transfected cells. J. Agric. Food Chem., submitted.

K. Augustin, J. Frank, S. Augustin, P. Langguth, V. Öhrvik, C.M. Witthöft, G. Rimbach, S. Wolffram (2008):
Green tea extracts lower serum folates in rats at very high dietary concentrations only and do not affect plasma folates in a human pilot study. J. Nutr., submitted.

T. Lenhardt, G. Vergnault, P. Grenier, D. Scherer, P. Langguth (2008):
Evaluation of nanosuspensions for absorption enhancement of poorly soluble drugs: In vitro transport studies across intestinal epithelial monolayers. AAPS Journal 10: 435-438

P. Buch, P. Langguth, M. Kataoka, S. Yamashita (2008):
IVIVC for fenofibrate immediate release tablets using a dissolution/permeation system. J. Pharm. Sci. 98: 2001-2009

S. Grube, P. Langguth, G.L. Amidon, H.E. Junginger, S. Kopp, K.K. Midha, V.P. Shah, S. STavchansky, J.B. Dressman, .M. Barends (2008):
Biowaiver monographs for immediate release solid oral dosage forms: Quinidine sulphate. J. Pharm. Sci. 98: 2238-2251

Y. Shirasaka, Y. Li, Y. Shibue, E. Kuraoka, H. Spahn-Langguth, Y. Kato, P. Langguth, I. Tamai (2008):
Concentration-dependent effect of naringinin on intestinal absorption of beta-blocker talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (OATP). Pharm. Res. 26: 560-567

2007

N.C. Alemdaroglu, S. Wolffram, J.-B. Boissel, E. Closs, H. Spahn-Langguth, P. Langguth (2007):
Tea extracts inhibit intestinal folate absorption in vitro. Planta Medica 73: 27-32.

N. Glube, E. Closs, P. Langguth (2007):
OCTN2 mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol. Pharm. 4: 160-168.

M. Jahn, Y. Mrestani, P. Langguth, R.H.H. Neubert (2007):
Capillary electrophoretic characterization of potential toxic labile iron in parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis 28: 2424-2429.

B. Beilmann, R. Kubiak, P. Graß, H. Häusler, P. Langguth (2007):
DPI formulations: interactive forces, coating effect and deposition pattern. AAPS PharmSciTech: 8(2) Article 31 DOI: 10.1208/pt 0802031.

A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, P. Langguth (2007):
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions in comparison to conventional suspensions of micronized drug. Adv. Drug Del. Rev. 59: 419-426.

M. Knöll, R. Lizio, H.U. Petereit, P. Langguth (2007):
Rotary agglomeration - a process for wet spheronization of bioadhesive micropellets. Pharm. Ind.: 69: 1194-1201.

N. Glube, A. Gießl, U. Wolfrum, P. Langguth (2007):
Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium. Nephron Exp. Nephrol. 107: 47-56 (DOI: 10.1159/000107804)

M. Tubic-Grozdanis, H. Spahn-Langguth, M.B. Bolger, P. Langguth (2007):
Validation of a physiologically based absorption model for P-gp substrates: Prediction of biopharmaceutic performance of controlled-release dosage forms. Pharm. Res. submitted.

2006

M. Tubic, D. Wagner, H. Spahn-Langguth, C. Weiler, R. Wanitschke, W.O. Böcher, P. Langguth (2006):
Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Eur. J. Pharm. Sci. 29: 231-239.

B. Beilmann, P. Langguth, H. Häusler, P. Grass (2006):
High performance liquid chromatography of lactose with evaporative light scattering detector applied to determine fine particle dose of carrier in dry powder inhalation products. J. Chromatog. A, 1107: 204-207.

Y. Shirasaka, M. Kawasaki, T. Sakane, H. Omatsu, Y. Moriya, T. Nakamura, T. Sakaeda, K. Okumura, P. Langguth, S. Yamashita (2006):
Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated transport. Drug Metabolism and Pharmacokinetics 21, 414-423.

M. Ofer, P. Langguth, H. Spahn-Langguth (2006):
Bidirectional membrane transport. Simulations of transport inhibition in uptake studies explain data obtained with flavonoids. Eur. J. Pharm. Sci. 29: 251-258.

M. Tubic, D. Wagner, H. Spahn-Langguth, M.B. Bolger, P. Langguth (2006):
In silico modelling of nonlinear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res. 23: 1712-1720.

2005

C. Hilgendorf, H. Spahn-Langguth, M. Rhedin, C.G. Regardh, B. Löwenadler, P. Langguth (2005):
Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
Molecular Pharmaceutics 2: 64-73

K. Brodka-Pfeiffer, H. Häusler, P. Graß, P. Langguth (2005):
Luftstrahlmahlung von homogenen Vormischungen aus Fenoterol-Hydrobromid und Glucose für den Einsatz in Pulverinhalatoren. Pharm. Ind. 67: 713-719.

P. Langguth, A. Hanafy, D. Frenzel, P. Grenier, A. Nhamias, T. Ohlig, G. Vergnault, H. Spahn-Langguth (2005):
Nanosuspension formulations for low soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound: Drug Dev. Ind. Pharm. 31: 319-329.

M. Ofer, S. Wolffram, A. Koggel, H. Spahn-Langguth, P. Langguth (2005):
Modulaion of drug transport by selected flavonoids: Involvement of P-gp and OCT? European Journal of Pharmaceutical Sciences, 25: 263-271.

U. Schmitt, A. Abou El-Ela, L.J. Guo, H. Glavinas, P. Krajesi, J.M. Baron, C. Tillmann, C. Hiemke, P. Langguth, S. Härtter (2005):
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J. Neural Transm. Electronic publication.

2004

C. Bott, M.W. Rudolph, A.R.J. Schneider, S. Schirrmacher, B. Skalsky, H.-U. Petereit, P. Langguth, J.B. Dressman, J. Stein (2004):
In vivo evaluation of a novel pH- and time-based multi-unit colonic drug deliver system. Aliment. Pharmacol. Ther. 20: 347-353.

A. Abou El-Ela, S. Härtter, U. Schmitt, Ch. Hiemke, P. Langguth (2004):
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds: Implication for pharmacokinetics of selected substrates. Journal of Pharmacy and Pharmacology 56: 967-975.

T. Mau, V. Hartmann, J. Burmeister, P. Langguth, H. Häusler (2004):
Development of a sterilizing in-place application for a production machine using vaporized hydrogen peroxide. PDA Journal pf Pharmaceutical Science and Technology 58: 130-146.

2003

D. Wagner, N. Glube, N. Berntsen, W. Tremel, P. Langguth (2003):
Different dissolution media lead to different crystal structures of the basic compound talinolol with impact on its dissolution and solubility. Drug Dev. Ind. Pharm. 29: 891-902

K. Brodka-Pfeiffer, H. Häusler, P. Graß, P. Langguth (2003):
Conditioning following powder micronization: Influence on particle growth of salbutamol sulfate. Drug Dev. Ind. Pharm. 29: 1077-1084.

M. Becker, P. Langguth, F. Moll (2003):
In-vitro-Freisetzung von Diclofenac aus halbfesten Arzneiformen. Pharm. Ind. 65: 1274-1278.

D. Werdenberg, R. Joshi, S. Wolffram, H.P. Merkle, P. Langguth (2003):
Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharmaceutics & Drug Disposition 24: 259-273.

S. Härtter, S. Hüwel, T. Lohmann, A. bou el Ela, P. Langguth, C. Hiemke, H.J. Galla (2003):
How does the benzamide antipsychotic amisulpiride get into the brain? An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 28: 1916-1922.

K. Brodka-Pfeiffer, P. Langguth, P. Graß, H. Häusler (2003):
Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur. J. Pharm. Biopharm. 56: 393-400.

C. Leisen, P. Langguth, B. Herber, C. Dressler, A. Koggel, H. Spahn-Langguth (2003):
Lipophilicites of baclofen ester produgs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein - Relevance for their permeation across the blood-brain barrier? Pharm. Res. 20: 772-778

2002

P. Anderle, P. Langguth, W. Rubas, H.P. Merkle (2002):
In vitro assessment of intestinal IGF-1 stability. J. Pharm. Sci. 91: 290-300.

P. Pietzonka, B. Rothen-Rutishauser, E. Walter, P. Langguth, H. Wunderli-Allenspach, H.P. Merkle (2002):
Transfer of lipophilic markers from polystyrene and PLGA nanoparticles to Caco-2 monolayers mimics particle uptake. Pharm. Res. 19: 595-601

K. Brodka-Pfeiffer, H. Häusler, P. Graß, G. Thieme, P. Langguth (2002):
Process for providing a stable crystalline form of salbutamol. Patentanmeldung EP 02 015 701.2.

P. Pietzonka, E. Walter, S. Duda-Johnera, P. Langguth, H.P. Merkle (2002):
Compromised integrity of excised porcine intestinal epithelium obtained from the abattoir affects the outcome of in vitro particle uptake studies. Eur. J. Pharm. Sci. 15: 39-47

2001

H. Spahn-Langguth, P. Langguth (2001):
Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12: 361-367

S.E. Shephard, P. Langguth, R.G. Panizzon (2001):
Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. Photodermatol. Photoimmunol Photomed. 17: 11-21.

A. Hanafy, P. Langguth, H. Spahn-Langguth (2001):
Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12: 405-415.

A. Hilgeroth, C. Dressler, S. Neuhoff, H. Spahn-Langguth, P. Langguth (2001):
Dimeric 4-aryl-1,4-dihydropyridines as novel HIV-1 protease inhibitors - affinities to intestinal P-glycoprotein. Pharmazie 55: 784-785.

T. Mau, V. Hartmann, P. Langguth, H. Häusler (2001):
Sterilisation von Oberflächen unter Einsatz von Wasserstoffperoxid in der Dampfphase. Pharm. Ind. 63: 1191-1196.

D. Wagner, H. Spahn-Langguth, A. Hanafy, A. Koggel, P. Langguth (2001):
Intestinal drug efflux: Formulation and food effects. Adv. Drug Del. Rev. 50: S13-S31.

C. Tannergren, P. Langguth, K.-J. Hoffmann (2001):
Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 56: 337-342.

2000

C. Hilgendorf, H. Spahn-Langguth, C.G. Regardh, E. Lipka, G.L. Amidon, P. Langguth (2000):
Caco-2 versus Caco-2/HT29-MTX cocultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier mediated transport. J. Pharm. Sci. 89: 63-75.

S. Neuhoff, P. Langguth, C. Dressler, T.B. Andersson, C.G. Regardh, H. Spahn-Langguth (2000):
Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int. J. Clin. Pharmacol. Ther. 38: 168-179.

1999

S. Döppenschmitt, P. Langguth, C.G. Regardh, T. Andersson, C. Hilgendorf, H. Spahn-Langguth (1999):
Characterization of binding properties to human intestinal multidrug transporter: Development of a P-glycoprotein specific radioligand-binding assay. J. Pharmacol. Exp. Ther. 288: 348-357

S. Döppenschmitt, H. Spahn-Langguth, C.G. Regardh, P. Langguth (1999):
The role of P-glycoprotein-mediated secretion in absorptive drug fluxes. J. Pharm. Sci. 88: 1067-1072.

1998

P. Anderle, E. Niederer, W. Rubas, C. Hilgendorf, H. Spahn-Langguth, H. Wunderli-Allenspach, Hans P. Merkle, P. Langguth (1998):
P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87: 757-762.

U. Gietz, R. Alder, P. Langguth, T. Arvinte, H.P. Merkle (1998):
Degradation mechanism and kinetics of recombinant hirudin (HV1) in aqueous solutions. Pharm. Res. 15: 1456-1462.

H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafi, P. Langguth (1998):
P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36: 16-24.

Y. Taki, T. Sakane, T. Nadai, H. Sezaki, G.L. Amidon, P. Langguth, S. Yamashita (1998):
First-pass metabolism of peptide drugs in rat perfused liver. J. Pharm. Pharmacol. 50: 1013-1018.

S. Döppenschmitt, H. Spahn-Langguth, C.G. Regardh, P. Langguth (1998):
Radioligand-binding assay employing P-glycoprotein overexpressing cells: Testing drug affinities to the secretory intestinal mulidrug transporter. Pharm. Res. 15: 1001-1006.

P. Langguth, M. Östgren (1998):
Intestinal permeability and absorption of peptide drugs. In: Clinical Pharmacology Vol. 15. Aspekte der intestinalen Absorption und der Modellentwicklung in Pharmakokinetik und Pharmakodynamik. T. Gramatte, M. Weiss (eds.), Zuckschwerdt Verlag, München

1997

V. Bohner, P. Langguth, C. Ottiger, H. Wunderli-Allenspach, D. Rognan, B. Rothen-Rutishauser, J.C. Perriard, S. Lang, J. Biber, H.P. Merkle (1997):
Structure-permeation relationship of Met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 cell monolayers. J. Pharm. Sci. 86: 846-853.

P. Langguth, A. Kubis, G. Krumbiegel, W. Lang, W. Wächter, H. Spahn-Langguth, R. Weyhenmeyer (1997):
Intestinal absorption mechanism, permeability and bioavailability of quaternary trospium from aqueous solution and novel formulations. Eur. J. Pharm. Biopharm. 43: 265-272.

P. Langguth, V. Bohner, H.P. Merkle, S. Wolffram, G.L. Amidon, S. Yamashita (1997):
The challenge of proteolytic enzymes in intestinal delivery of peptide drugs. J. Controlled Release, 46: 39-57.

1996

U. Wetterich, E. Mutschler, B. Terhaag, H. Spahn-Langguth, P. Langguth (1996):
Evidence for intestinal secretion as additional clearance pathway of talinolol enantiomers: Concentration-and dose-dependent absorption in vitro and in ivo. Pharm. Res. 13, 514-522.

S. Lang, P. Langguth, R. Oschmann, B. Traving, H.P. Merkle (1996):
Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. J. Pharm. Pharmacol. 48: 1190-1196.

J. Heizmann, P. Langguth, A. Biber, R. Oschmann, H.P. Merkle, S. Wolffram (1996):
Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides 17: 1083-1089.

H.L. Luessen, V. Bohner, D. Pérard, P. Langguth, J.C. Verhoef, A.G. de Boer, H.P. Merkle, H.E. Junginger (1996):
Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int. J. Pharm. 141: 39-52.

P. Ader, B. Grenacher, P. Langguth, S. Wolffram (1996):
Cinnamate uptake by rat small intestine: Transport kinetics and transepithelial transfer. Experimental Physiology 81, 943-955.

1995

E. Lipka, I. Lee, P. Langguth, H. Spahn-Langguth, E. Mutschler, G.L. Amidon (1995):
Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharmacokin. Biopharm. 23: 267-286.

P. Langguth, W. Möhrke, H. Möhler, H. Spahn-Langguth:
Drug absorption via intestinal versus nasal mucosae: Dependence of rate and extent of systemic availability of tranylcypromine enantiomers upon the application site. Biopharm. Drug Dispos., eingereicht.

Y. Taki, T. Sakane, T. Nadai, H. Sezaki, P. Langguth, S. Yamashita (1995):
Gastrointestinal absorption of peptide drugs: Quantitative evaluation of the degradation and permeation of metkephamid in rat small intestine. J. Pharmacol. Exp. Ther. 274: 373-377.

1994

C. Gido, E. Mutschler, P. Langguth (1994):
Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles. Pharm. Res. 11: 800-808.

P. Langguth, V. Bohner, J. Biber, H.P. Merkle (1994):
Metabolism and transport of the pentapeptide metkephamid by brush-border membrane vesicles of rat intestine. J. Pharm. Pharmacol. 46: 34-40.

P. Langguth, H.P. Merkle, G.L. Amidon (1994):
Oral absorption of peptides: The effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res., 11, 528-535.

P. Langguth, G. Breves, A. Stöckli, H.P. Merkle, S. Wolffram (1994):
Colonic absorption and bioavailability of a pentapeptide drug in the rat. Pharm. Res., 11, 1642-1647.

P. Langguth, K.M. Lee, H. Spahn-Langguth, G.L. Amidon (1994):
Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug. Dispos., 15, 719-746.

1993

H. Weber-Grandke, G. Hahn, E. Mutschler, W. Möhrke, P. Langguth, H. Spahn-Langguth (1993):
The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br. J. Clin. Pharmacol., 36, 366-368.

C. Gido, J. Kreuter, P. Langguth, E. Mutschler, G. Winter, H. Woog (1993):
Conventional versus novel dissolution conditions for in vitro testing of parenteral slow release formulations and application to doxepin parenteral dosage forms. Die Pharmazie, 48, 764-769.

1992

H. Spahn-Langguth, G. Hahn, E. Mutschler, W. Möhrke, P. Langguth (1992):
Enantiospecific HPLC assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. J. Chromatog. Biomed. Appl. 584, 229-237.

1991

P. Langguth, R. Alder, H.P. Merkle (1991):
Studies on the stability of Aspartame I: Specific and reproducible HPLC assay for Aspartame and its potential degradation products and applications to acid hydrolysis of Aspartame. Die Pharmazie 46, 188-192.

1990

P. Langguth, P.J. Khan, E.R. Garrett (1990):
Pharmacokinetics of morphine and its surrogates XI: Effect of simultaneously administered naltrexone and morphine on the pharmacokinetics and pharmacodynamics of each in the dog. Biopharm. Drug Dispos. 11, 419-444.

P. Langguth, H. Spahn, H.P. Merkle (1990):
Fluorescence assay for small peptides and amino acids: HPLC determination of selected substrates using activated S-flunoxaprofen as a chiral derivatizing agent. J. Chromatogr. Biomed. Appl. 528, 55-64.

H. Spahn, P. Langguth (1990):
Chiral amines derived from 2-arylpropionic acids: Novel reagents for the LC fluorescence assay of optically active carboxylic acid xenobiotics. Pharm. Res. 7, 1262-1268.

H. Spahn, W. Henke, P. Langguth, J. Schloos, E. Mutschler (1990):
Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization. Arch. Pharm. (Weinheim) 323, 465-469.

1987

P. Langguth, E. Mutschler (1987):
Lipophilisation of hydrophilic compounds - consequences on transepidermal and intestinal transport of trospium. Arzneim. Forsch. / Drug. Res. 37 (II), 1362-1366.

H. Spahn, P. Langguth, D. Krauß, W. Kirch, E. Mutschler (1987):
Pharmacokinetics of atenolol and metoprolol administered together with piroxicam. Arch. Pharm (Weinheim) 320, 103-107.

1986

P. Langguth, H. Spahn, E. Mutschler (1986):
Variations of in vitro nitroglycerine permeation through human skin. Pharm. Res. 3 (1), 61-63.

P. Langguth, H. Spahn, E. Mutschler, K. Hübner (1986):
An approach to reduce the number of skin samples in testing transepidermal permeation of drugs. J. Pharm. Pharmacol. 38: 726-730.

H. Spahn, P. Langguth, W. Kirch, E.E. Ohnhaus, E. Mutschler (1986):
Pharmacokinetics of salicylates administered together with metoprolol. Arzneim. Forsch. / Drug. Res. 36 (II); 1697-1699.